<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37183233</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Serum pentraxin 3 in systemic lupus erythematosus: A potential indicator of cutaneous disease activity.</ArticleTitle><Pagination><StartPage>873</StartPage><EndPage>879</EndPage><MedlinePgn>873-879</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231175627</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although skin manifestations are common in systemic lupus erythematosus (SLE), there is still a lack of a diagnostic marker for cutaneous involvement. Pentraxin3 (PTX3) has been studied in SLE patients; however, it has not been investigated in relation to cutaneous manifestations.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the serum PTX3 level in SLE patients, and to investigate its relationship with disease activity as well as with variable skin manifestations.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Thirty-four patients with SLE (17 patients with skin manifestations and 17 without) and 30 healthy subjects were included in the study. Patients were evaluated clinically for systemic and skin manifestations of SLE. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2k) and Cutaneous Lupus Erythematosus Activity and Severity Index (CLASI) scores were calculated. Serum level of PTX3 was measured in patients and controls using ELISA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher serum PTX3 level was found in SLE patients compared to controls (<i>p</i> &lt; 0.001). Patients with skin manifestations showed higher SLEDAI-2k scores and had higher PTX3 level compared to those without skin manifestations (<i>p</i> = 0.015 and <i>p</i> &lt; 0.001, respectively). PTX3 showed higher levels in association with malar rash (<i>p</i> &lt; 0.001), mucosal ulcers (<i>p</i> &lt; 0.001), alopecia (<i>p</i> &lt; 0.001), and purpuric eruption (<i>p</i> = 0.002). Moreover, PTX3 level positively correlated with CLASI scores (<i>p</i> &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results reinforce the important role of Pentraxin3 in SLE patients with skin manifestations, and it may be considered an interesting biomarker for the pattern and extent of cutaneous involvement in SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Sahar A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Dermatology and Venereology, Faculty of Medicine, Assiut University, Assiut, Egypt.</Affiliation><Identifier Source="RINGGOLD">2068866</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awad</LastName><ForeName>Sara M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0003-0664-6358</Identifier><AffiliationInfo><Affiliation>Department of Dermatology and Venereology, Faculty of Medicine, Assiut University, Assiut, Egypt.</Affiliation><Identifier Source="RINGGOLD">2068866</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamal</LastName><ForeName>Rania M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University, Assiut, Egypt.</Affiliation><Identifier Source="RINGGOLD">2068866</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaber</LastName><ForeName>Marwa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Faculty of Medicine, Assiut University, Assiut, Egypt.</Affiliation><Identifier Source="RINGGOLD">2068797</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Safaa M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Dermatology and Venereology, Faculty of Medicine, Assiut University, Assiut, Egypt.</Affiliation><Identifier Source="RINGGOLD">2068866</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammam</LastName><ForeName>Nevin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University, Assiut, Egypt.</Affiliation><Identifier Source="RINGGOLD">2068866</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>148591-49-5</RegistryNumber><NameOfSubstance UI="C077657">PTX3 protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000721270">malar rash</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="Y">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CLASI</Keyword><Keyword MajorTopicYN="N">Pentraxin 3</Keyword><Keyword MajorTopicYN="N">SLEDAI-2k</Keyword><Keyword MajorTopicYN="N">Systemic Lupus Erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>14</Day><Hour>23</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37183233</ArticleId><ArticleId IdType="doi">10.1177/09612033231175627</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>